These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25539290)

  • 1. Specific pharmacology of long-acting, extended-release, and sustained-release opioids for the treatment of chronic nonmalignant pain.
    Sloan PA; Davis MP; Gamier P
    J Opioid Manag; 2015; Suppl():21-41. PubMed ID: 25539290
    [No Abstract]   [Full Text] [Related]  

  • 2. General pharmacology of long-acting, extended-release, and sustained-release opioids for the treatment of chronic nonmalignant pain.
    Davis MP; Gamier P; Sloan PA
    J Opioid Manag; 2015; Suppl():11-20. PubMed ID: 25539289
    [No Abstract]   [Full Text] [Related]  

  • 3. Case studies of long-acting, extended-release, and sustained-release opioids for the treatment of chronic nonmalignant pain.
    Sloan PA
    J Opioid Manag; 2015; Suppl():42-6. PubMed ID: 25539291
    [No Abstract]   [Full Text] [Related]  

  • 4. Extended-release and long-acting opioids for chronic pain management.
    Sloan PA; Davis MP
    J Opioid Manag; 2015; Suppl():3-10. PubMed ID: 25539288
    [No Abstract]   [Full Text] [Related]  

  • 5. A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain.
    Arora S; Setnik B; Michael D; Hudson JD; Clemmer R; Meisner P; Pixton GC; Goli V; Sommerville KW
    J Opioid Manag; 2014; 10(6):423-36. PubMed ID: 25531960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioids for chronic noncancer pain: still no evidence for superiority of sustained-release opioids.
    Pedersen L; Fredheim O
    Clin Pharmacol Ther; 2015 Feb; 97(2):114-5. PubMed ID: 25670511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine buccal film (Belbuca) for chronic pain.
    Med Lett Drugs Ther; 2016 Apr; 58(1492):47-8. PubMed ID: 27049508
    [No Abstract]   [Full Text] [Related]  

  • 8. Open-label study to evaluate the efficacy and safety of extended-release hydromorphone in patients with chronic neuropathic pain.
    Nalamachu S; Ruck D; Nalamasu R; Fasbinder S; Bansal R
    J Opioid Manag; 2013; 9(1):43-9. PubMed ID: 23709303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypogonadism in men with chronic pain linked to the use of long-acting rather than short-acting opioids.
    Rubinstein AL; Carpenter DM; Minkoff JR
    Clin J Pain; 2013 Oct; 29(10):840-5. PubMed ID: 24384986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of extended-release opioid analgesics for the treatment of chronic pain.
    Gudin JA
    J Pain Palliat Care Pharmacother; 2013 Mar; 27(1):49-61. PubMed ID: 23527669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: pooled analysis of randomized studies.
    Merchant S; Provenzano D; Mody S; Ho KF; Etropolski M
    J Opioid Manag; 2013; 9(1):51-61. PubMed ID: 23709304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study.
    Rauck RL; Nalamachu S; Wild JE; Walker GS; Robinson CY; Davis CS; Farr SJ
    Pain Med; 2014 Jun; 15(6):975-85. PubMed ID: 24517082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on extended-release opioids in pain management.
    Sloan P
    Expert Opin Drug Deliv; 2014 Feb; 11(2):155-8. PubMed ID: 24299558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary care considerations of the pharmacokinetics and clinical use of extended-release opioids in treating patients with chronic noncancer pain.
    Nicholson B
    Postgrad Med; 2013 Jan; 125(1):115-27. PubMed ID: 23391677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients.
    Setnik B; Roland CL; Goli V; Sommerville K; Webster L
    J Opioid Manag; 2013; 9(2):139-50. PubMed ID: 23709323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain.
    Vondrackova D; Leyendecker P; Meissner W; Hopp M; Szombati I; Hermanns K; Ruckes C; Weber S; Grothe B; Fleischer W; Reimer K
    J Pain; 2008 Dec; 9(12):1144-54. PubMed ID: 18708300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment strategies to overcome end-of-dose failure with oral and transdermal opioids.
    Hall LM; O'Lenic K
    J Pharm Pract; 2012 Oct; 25(5):503-9. PubMed ID: 23011962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the case for prescribing long-acting opioids over short-acting opioids for patients with chronic pain? A critical review.
    Rauck RL
    Pain Pract; 2009; 9(6):468-79. PubMed ID: 19874536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study.
    Hermanns K; Junker U; Nolte T
    Expert Opin Pharmacother; 2012 Feb; 13(3):299-311. PubMed ID: 22224497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid analgesics: does potency matter?
    Passik SD; Webster L
    J Opioid Manag; 2014; 10(4):263-75. PubMed ID: 25162606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.